Want to see CATX full AI Analyst Report?
Top Page
Perspective Therapeutics
(NYSE MKT:CATX)
Select Model
Select Model
Rating:52Neutral
Price Target:
$3.00
▲(3.09% Upside)
Action:Reiterated
Date:08/11/26
The score is held back primarily by very weak operating performance (minimal/volatile revenue, large losses) and persistent cash burn, partially offset by a low-leverage balance sheet and a series of positive pipeline/manufacturing progress updates. Technicals and valuation provide limited near-term support, with the stock trading below key longer-term moving averages and a negative P/E due to losses.
Positive Factors
Low leverage and strengthened equity base
Very low debt and a materially larger equity base reduce near-term financial distress risk and give management flexibility to fund R&D, manufacturing buildout and trials without immediate refinancing. This balance-sheet strength supports execution through mid-term clinical milestones and partnership talks.
Negative Factors
Persistent heavy cash burn
Sustained negative operating and free cash flows mean the company must continue to access external capital to fund trials and manufacturing. Ongoing burn increases dilution and limits strategic optionality; absent clinical or partnership milestones, financing dependence poses multi-quarter execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and strengthened equity base
Very low debt and a materially larger equity base reduce near-term financial distress risk and give management flexibility to fund R&D, manufacturing buildout and trials without immediate refinancing. This balance-sheet strength supports execution through mid-term clinical milestones and partnership talks.
Read all positive factors
Perspective Therapeutics (CATX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$365.29M
Dividend YieldN/A
Average Volume (3M)2.11M
Price to Earnings (P/E)―
Beta (1Y)1.55
Revenue Growth-66.88%
EPS Growth-0.42%
CountryUS
Employees165
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.43
Shares Outstanding114,151,665
10 Day Avg. Volume1,481,951
30 Day Avg. Volume2,113,515
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-2.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.80Price Target Upside339.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.99
Revenue Forecast (FY)$389.88K
Perspective Therapeutics Business Overview & Revenue Model
Company Description
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solution...
How the Company Makes Money
null...
Perspective Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
72
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 409.00K | 0.00 | 1.45M | 1.43M | 7.10M | 10.79M |
| Gross Profit | -2.50M | 0.00 | -852.00K | 1.43M | 1.63M | 4.62M |
| EBITDA | -116.21M | -100.80M | 10.46M | -39.96M | -14.84M | -7.39M |
| Net Income | -116.43M | -103.12M | -79.28M | -46.51M | -14.67M | -7.15M |
Balance Sheet | ||||||
| Total Assets | 392.02M | 266.97M | 341.10M | 97.89M | 58.09M | 67.25M |
| Cash, Cash Equivalents and Short-Term Investments | 236.88M | 144.74M | 226.92M | 9.24M | 43.76M | 60.35M |
| Total Debt | 2.37M | 3.25M | 4.06M | 2.55M | 524.00K | 652.00K |
| Total Liabilities | 68.16M | 59.94M | 50.43M | 22.71M | 3.45M | 2.86M |
| Stockholders Equity | 323.86M | 207.03M | 290.67M | 75.18M | 54.64M | 64.39M |
Cash Flow | ||||||
| Free Cash Flow | -121.19M | -95.23M | -72.71M | -37.98M | -10.68M | -7.98M |
| Operating Cash Flow | -93.07M | -82.48M | -18.29M | -36.91M | -10.40M | -7.71M |
| Investing Cash Flow | -52.01M | 41.23M | -218.93M | 24.37M | -28.99M | -284.00K |
| Financing Cash Flow | 164.71M | 10.30M | 289.38M | 785.00K | 28.00K | 56.00K |
Perspective Therapeutics Technical Analysis
Positive
2.91
Price Trends
3.08
Positive
3.58
Negative
3.51
Negative
Market Momentum
<0.01
Negative
55.66
Neutral
76.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CATX, the sentiment is Positive. The current price of 2.91 is below the 20-day moving average (MA) of 2.99, below the 50-day MA of 3.08, and below the 200-day MA of 3.51, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.66 is Neutral, neither overbought nor oversold. The STOCH value of 76.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CATX.
Perspective Therapeutics Risk Analysis
Perspective Therapeutics disclosed 56 risk factors in its most recent earnings report. Perspective Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Perspective Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | $341.30M | 33.79 | 22.14% | ― | 16.79% | 45.17% | |
67 Neutral | $350.41M | 24.39 | 10.30% | ― | 25.21% | 6.14% | |
55 Neutral | $324.50M | -4.05 | 273.71% | ― | 25.25% | -9.85% | |
52 Neutral | $365.29M | -2.24 | -41.56% | ― | -66.88% | -0.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $73.59M | -0.88 | -51.88% | ― | 25.74% | -26.25% | |
42 Neutral | $122.49M | -0.98 | -43.59% | ― | 21.96% | -44.65% |
* Healthcare Sector Average
CATX
Perspective Therapeutics
3.20
-0.49
-13.28%
ELMD
Electromed
41.22
21.53
109.34%
QTRX
Quanterix
2.59
-2.36
-47.68%
VMD
Viemed Healthcare
9.20
2.28
32.95%
NNOX
Nano-X Imaging
1.00
-3.26
-76.60%
TLSI
TriSalus Life Sciences
5.27
0.41
8.44%
Perspective Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Perspective Therapeutics Reports Q2 Results and Pipeline Progress
Positive
Aug 10, 2026
On August 10, 2026, Perspective Therapeutics reported second-quarter 2026 results and recent business milestones, highlighting continued clinical progress across its 212Pb pipeline and preparations for its first Phase 3 trial. The company detailed...
Business Operations and Strategy
Perspective Therapeutics Advances 212Pb Radiopharmaceutical Oncology Platform
Positive
Aug 3, 2026
On August 3, 2026, Perspective Therapeutics updated its corporate presentation highlighting progress across its 212Pb-based oncology portfolio and integrated radiopharmaceutical platform. The materials emphasize a theranostic strategy, regional pr...
Business Operations and StrategyProduct-Related Announcements
Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline
Positive
Jul 1, 2026
On July 1, 2026, Perspective Therapeutics, Inc. updated its corporate presentation to highlight progress on its 212Pb-based radiopharmaceutical pipeline and integrated manufacturing strategy. The company emphasized its theranostic approach, target...
Business Operations and StrategyProduct-Related Announcements
Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline
Positive
Jun 1, 2026
On June 1, 2026, Perspective Therapeutics, Inc. updated its corporate presentation to highlight progress in its pipeline of 212Pb-based radiopharmaceuticals for solid tumors and to showcase its vertically integrated model for isotope production an...
Executive/Board ChangesShareholder Meetings
Perspective Therapeutics shareholders approve directors and governance items
Positive
May 27, 2026
On May 27, 2026, Perspective Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where 85.85% of the 114,017,755 outstanding common shares were represented, establishing a quorum for voting on board elections, auditor ratification, an...
Business Operations and Strategy
Perspective Therapeutics Showcases Strong Interim Radiopharma Data
Positive
May 22, 2026
On May 21, 2026, Perspective Therapeutics reported interim clinical data that will be presented at the 2026 ASCO Annual Meeting, highlighting consistent efficacy and safety profiles across all three of its radiopharmaceutical programs. Updated [21...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Perspective Therapeutics Highlights Q1 Progress and Strengthened Finances
Positive
May 11, 2026
Perspective Therapeutics reported first-quarter 2026 results on May 11, 2026, highlighting progress across three clinical-stage oncology programs—VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma and PSV359 for FAP-positive solid ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.